Gemmus Pharma

Based in San Francisco, California, Gemmus Pharma is a privately held biotechnology company that develops host-targeted treatments for moderate to life-threatening influenza infections using repurposed drugs. The organization focuses on utilizing EP2 and EP4 agonists that were previously in-licensed from a major pharmaceutical firm to create its therapeutic pipeline. Operating with a specialized team of five employees, the enterprise advances its lead candidate through a defined clinical development plan. Under the executive leadership of Chief Executive Officer Daryl Faulds and President William Guilford, the firm has successfully submitted a pre-Investigational New Drug package to the FDA. The business is financed through venture capital, including a $3.3 million Series B funding round aimed at progressing its primary flu medication toward commercialization. Gemmus Pharma was officially established as a corporate entity in August 2007.